Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic obese patients
2019-002262-12Phase 2Active
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dapagliflozin in obesity and glomerular hyperfiltration, sponsored by Hospital Universitari Germans Trias i Pujol. Primary endpoint: Decrease in measured glomerular filtration rate. Started Sep 2021; status: active.
02
Drugs
dapagliflozin
03
Conditions
obesityglomerular hyperfiltration
Beyond the preview
Go deeper on 2019-002262-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002262-12.